Shows
BiotechTV - NewsAI x Bio Summit: Nimbus Therapeutics' new CEO and head of R&D describe how AI is an isn't used in the company's R&D processCEO Abbas Kazimi and President of R&D Peter Tummino discuss how AI integrates into their discovery and clinical development work, and walk us through some of the company's current programs.2025-07-2211 min
BioBossAbbas Kazimi: CEO of Nimbus TherapeuticsAbbas Kazimi, CEO of Nimbus Therapeutics, shares his insights about leadership in biopharma and how Nimbus is working to design and develop small molecule medicines capable of improving patients' lives.2025-06-2847 min
HealthscapeEpisode 30: Positioning for Success and Taking Risks in Biotech with Abbas Kazimi, Chief Business Officer of Nimbus TherapeuticsIn this episode, Irtaza Haider and Pam Divack sit down with Abbas Kazimi, Chief Business Officer of Nimbus Therapeutics. They discuss Abbas' career journey and role at Nimbus, the complexity of the biotech landscape and positioning your company for success, and being bold in biopharma. Abbas also offers insights into the importance of developing your leadership style and advice for MBA students and aspiring healthcare leaders.
If you have any ideas for new episodes, please reach out to the Kellogg Healthcare Club. 2024-03-1837 min
Pathfinders in BiopharmaHow Biotech M&A is Redefining the Strategic LandscapeGiven current macro and regulatory headwinds, determining the optimal time to sell a biotech company is a multifaceted decision that requires careful consideration of several key factors. Hear from industry veterans Ted Love, Marc de Garidel, and Abbas Kazimi who share their insights on a new era of M&A in a panel moderated by RBC Capital Markets Analysts Dr. Brian Abrahams, Dr. Luca Issi and Dr. Gregory Renza. 2023-06-2325 min
Biotech2050 Podcast23. Abbas Kazimi, VP of Business Development, Nimbus TherapeuticsAbbas Kazimi is the Vice President, Head of Business Development at Nimbus Therapeutics, a biotechnology company harnessing quantum mechanics and computational approaches to structural biology to design breakthroughs in medicine. Abbas joined Nimbus in 2014 as Director of Business Development and has driven several of the company’s key transactions that have brought over $775M into Nimbus through financings and transactions, including the exclusive licensing agreement with Genentech, the sale of Nimbus’ clinical NASH program to Gilead in and the multiple strategic alliances with Celgene.
Prior to joining Nimbus, Abbas spent a decade in planning, advising, and exec...2020-07-2831 min
Biotech 2050 Podcast23. Abbas Kazimi, VP of Business Development, Nimbus TherapeuticsAbbas Kazimi is the Vice President, Head of Business Development at Nimbus Therapeutics, a biotechnology company harnessing quantum mechanics and computational approaches to structural biology to design breakthroughs in medicine. Abbas joined Nimbus in 2014 as Director of Business Development and has driven several of the company’s key transactions that have brought over $775M into Nimbus through financings and transactions, including the exclusive licensing agreement with Genentech, the sale of Nimbus’ clinical NASH program to Gilead in and the multiple strategic alliances with Celgene.
Prior to joining Nimbus, Abbas spent a decade in planning, advising, and executing strategic transactions for life...2020-07-2231 min